About

John McLaughlin is a Principal Scientist at Intertek Melbourn, where he specialises in LC-MS analysis for the Biologics team. He manages LC-MS work, covering a wide range of samples with expertise in small-molecule
impurities in pharmaceuticals and large-molecule proteins and oligonucleotides in inhaled formulation products. His focus is on method development and validation in GxP regulated environments. Mr McLaughlin earned
his master’s degree in Chemistry with Medicinal Chemistry from the University of Warwick (UK) in 2018.

Prior to joining Intertek, he worked in various research organisations, focusing on bioanalysis of small and large molecules.

Contributions

EXPERT VIEW

TRACE ANALYTICAL CONSIDERATIONS WHEN REFORMULATING pMDIS WITH NEXT-GENERATION LOW-GWP PROPELLANT SYSTEMS

Mark Parry, John McLaughlin and Tino Otte discuss the necessary studies required to understand the nitrosamine formation and leachables profiles of new pMDI propellants with lower global warming potentials as part of the pharmaceutical industry’s drive to reduce its emissions and environmental impact.